<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974740</url>
  </required_header>
  <id_info>
    <org_study_id>33/0136-Diator</org_study_id>
    <nct_id>NCT00974740</nct_id>
  </id_info>
  <brief_title>DIATOR-Diabetes Intervention With Atorvastatin</brief_title>
  <official_title>DIATOR - Diabetes Intervention With Atorvastatin. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Atorvastatin on Residual Beta-cell Function and Glycemic Control in Patients With Newly Diagnosed Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on
      beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent
      immunomodulator. In this study the effects of 80 mg atorvastatin per day on preservation of
      beta-cell function in recent onset type 1 diabetes were studied, as determined by stimulated
      C-peptide levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study were as follows:

        -  To assess the effect of atorvastatin on pancreatic beta-cell function as measured by
           C-peptide after a liquid mixed meal stimulation in patients with newly diagnosed type 1
           diabetes,

        -  To assess the effect on metabolic control as measured by HbA1c and insulin requirements,

        -  To assess safety and tolerability of atorvastatin in subjects with newly diagnosed type
           1 diabetes,

        -  To assess the effect on risk factors of diabetic complications as indicated by changes
           in lipids and CRP, and

        -  To assess the effect on systemic immune abnormalities as measured by effects on
           beta-cell autoantibodies, blood cytokines and chemokines on protein and transcriptional
           level.

      Study duration: 18 months
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    for lack of recruitment
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide after a liquid mixed meal stimulation</measure>
    <time_frame>at randomization, after 12 months, and after 18 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>at randomization, after 6, 12, and 18 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose</measure>
    <time_frame>at randomization, and after 3, 6, 12, and 18 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>at randomization, and after 3, 6, 12, and 18 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>at randomization, and after 3, 6, 12, and 18 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma CRP</measure>
    <time_frame>at randomization, and after 3, 12, and 18 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>atorvastatin matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>atorvastatin matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)</description>
    <arm_group_label>atorvastatin</arm_group_label>
    <other_name>Sortis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin matching placebo</intervention_name>
    <description>atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)</description>
    <arm_group_label>atorvastatin matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by
             the ADA criteria at least two weeks but not later than 3 months after start of insulin
             treatment

          -  Age 18 to 39 years, inclusive

          -  Male patient or female patient using adequate contraceptive methods

          -  Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA

        Exclusion Criteria:

          -  History of a malignancy

          -  Presence of a clinically significant hepatic or renal disease, as indicated, but not
             limited to a serum creatinine elevated more than ten percent above the upper limit of
             normal, elevation of AST or ALT more than 3 times the upper limit of normal

          -  Any other acute or chronic condition that may affect the patient's response to
             treatment or might be associated with an increased risk for the patient to
             participate, as judged by the investigator

          -  Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive,
             lipid-lowering, or antidiabetic drugs other than insulin

          -  Pregnant or nursing women or women intending to become pregnant

          -  Known or suspected allergy to atorvastatin or any component of thr trial product

          -  Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of
             normal

          -  Patients who had a severe blood loss (&gt;= 400 mL, e.g. blood donation) within 2 months
             prior to visit 2

          -  Any significant laboratory abnormality

          -  A serum LDL-cholesterol above 150 mg/dL at time of screening

          -  Unwillingness to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DDZ Deutsches Diabetes Zentrum, Düsseldorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes-Zentrum Mergentheim</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Havelhöhe</name>
      <address>
        <city>Berlin</city>
        <zip>14089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Emil von Behring</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Friedhelm Schmitten</name>
      <address>
        <city>Bestwig-Ramsbeck</city>
        <zip>59909</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DDZ Deutsches Diabetes Zentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs Krankenhaus</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Krankenhaus, Med. Klinik</name>
      <address>
        <city>Köln</city>
        <zip>50968</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Gerhard Willms</name>
      <address>
        <city>Leverkusen</city>
        <zip>51373</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Heinz-Georg Ley</name>
      <address>
        <city>Marl</city>
        <zip>45770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis, Angiologie</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Werner Stürmer</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

